BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25373323)

  • 1. Gene expression profiling of histologically normal breast tissue in females with human epidermal growth factor receptor 2‑positive breast cancer.
    Zubor P; Hatok J; Moricova P; Kapustova I; Kajo K; Mendelova A; Sivonova MK; Danko J
    Mol Med Rep; 2015 Feb; 11(2):1421-7. PubMed ID: 25373323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression abnormalities in histologically normal breast epithelium from patients with luminal type of breast cancer.
    Zubor P; Hatok J; Moricova P; Kajo K; Kapustova I; Mendelova A; Racay P; Danko J
    Mol Biol Rep; 2015 May; 42(5):977-88. PubMed ID: 25407308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.
    Cuadros M; Cano C; López FJ; López-Castro R; Concha A
    Pathobiology; 2013; 80(1):32-40. PubMed ID: 22832278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
    Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
    J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis.
    Merdad A; Karim S; Schulten HJ; Dallol A; Buhmeida A; Al-Thubaity F; Gari MA; Chaudhary AG; Abuzenadah AM; Al-Qahtani MH
    Anticancer Res; 2014 Mar; 34(3):1355-66. PubMed ID: 24596383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer.
    Dahl E; Kristiansen G; Gottlob K; Klaman I; Ebner E; Hinzmann B; Hermann K; Pilarsky C; Dürst M; Klinkhammer-Schalke M; Blaszyk H; Knuechel R; Hartmann A; Rosenthal A; Wild PJ
    Clin Cancer Res; 2006 Jul; 12(13):3950-60. PubMed ID: 16818692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERBB2 overexpression triggers transient high mechanoactivity of breast tumor cells.
    Martin M; Müller K; Cadenas C; Hermes M; Zink M; Hengstler JG; Käs JA
    Cytoskeleton (Hoboken); 2012 May; 69(5):267-77. PubMed ID: 22407943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells.
    Pommier SJ; Quan GG; Christante D; Muller P; Newell AE; Olson SB; Diggs B; Muldoon L; Neuwelt E; Pommier RF
    Ann Surg Oncol; 2010 Feb; 17(2):613-23. PubMed ID: 19838757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
    Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
    Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer.
    Zhang D; Salto-Tellez M; Putti TC; Do E; Koay ES
    Mod Pathol; 2003 Jan; 16(1):79-84. PubMed ID: 12527717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical validation of a customized multiple signature microarray for breast cancer.
    Tan BK; Tan LK; Yu K; Tan PH; Lee M; Sii LH; Wong CY; Ho GH; Yeo AW; Chow PK; Koong HN; Yong WS; Lim DT; Ooi LL; Soo KC; Tan P
    Clin Cancer Res; 2008 Jan; 14(2):461-9. PubMed ID: 18223220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
    J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semaphorin-plexin signalling genes associated with human breast tumourigenesis.
    Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR
    Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients.
    Tripathi A; King C; de la Morenas A; Perry VK; Burke B; Antoine GA; Hirsch EF; Kavanah M; Mendez J; Stone M; Gerry NP; Lenburg ME; Rosenberg CL
    Int J Cancer; 2008 Apr; 122(7):1557-66. PubMed ID: 18058819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras AK; Kalogeras KT; Dimopoulos MA; Wirtz RM; Dafni U; Briasoulis E; Pectasides D; Gogas H; Christodoulou C; Aravantinos G; Zografos G; Timotheadou E; Papakostas P; Linardou H; Razis E; Economopoulos T; Kalofonos HP; Fountzilas G;
    Br J Cancer; 2008 Dec; 99(11):1775-85. PubMed ID: 18985033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.
    Van Laere SJ; Van der Auwera I; Van den Eynden GG; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
    Br J Cancer; 2007 Sep; 97(5):659-69. PubMed ID: 17700572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.